Editas Medicine Inc (EDIT)

2.655 -0.12 (-4.15%) USD  |  NASDAQ  |  Nov 15, 12:39
More

Editas Medicine Cash and Short Term Investments (Quarterly): 265.09M for Sept. 30, 2024

Cash and Short Term Investments (Quarterly) Chart

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2014. Upgrade now.
Date Value
September 30, 2024 265.09M
June 30, 2024 279.11M
March 31, 2024 296.17M
December 31, 2023 323.11M
September 30, 2023 349.62M
June 30, 2023 431.97M
March 31, 2023 318.44M
December 31, 2022 344.27M
September 30, 2022 419.62M
June 30, 2022 452.56M
March 31, 2022 488.36M
December 31, 2021 499.84M
September 30, 2021 557.84M
June 30, 2021 610.55M
March 31, 2021 625.33M
December 31, 2020 402.11M
September 30, 2020 495.30M
June 30, 2020 598.72M
March 31, 2020 414.99M
Date Value
December 31, 2019 457.14M
September 30, 2019 332.62M
June 30, 2019 317.93M
March 31, 2019 342.06M
December 31, 2018 368.96M
September 30, 2018 337.49M
June 30, 2018 344.08M
March 31, 2018 358.82M
December 31, 2017 329.14M
September 30, 2017 295.69M
June 30, 2017 324.80M
March 31, 2017 351.55M
December 31, 2016 185.32M
September 30, 2016 199.87M
June 30, 2016 217.65M
March 31, 2016 229.20M
December 31, 2015 143.18M
September 30, 2015 155.30M
December 31, 2014 10.62M

Cash and Short Term Investments Definition

Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

265.09M
Minimum
Sep 2024
625.33M
Maximum
Mar 2021
431.51M
Average
425.79M
Median

Cash and Short Term Investments (Quarterly) Benchmarks

EyePoint Pharmaceuticals Inc 253.79M
Cassava Sciences Inc 148.98M
Adverum Biotechnologies Inc 153.24M
Regenxbio Inc 255.46M
Apellis Pharmaceuticals Inc 396.86M